Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 6/20 | 0.52 |
| ▸ | NOS3 | P29474 | 4/20 | 0.52 |
| ▸ | NOS1 | P29475 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL18986103 | 0.98 | NOS2 (0.50) | NOS2NOS3NOS1RAB9ADYRK1A | |
| SCHEMBL5949408 | 0.84 | LMNA (0.37) | NOS2NOS3NOS1RAB9A | |
| Hydrochloric Acid SCHEMBL6629648 | 0.81 | LMNA (0.36) | NOS2NOS3NOS1RAB9A | |
| SCHEMBL23064147 | 0.80 | NOS3 (0.54) | NOS2NOS3NOS1 | |
| SCHEMBL21672278 | 0.80 | NOS2 (0.54) | NOS2NOS3NOS1RAB9A | |
| SCHEMBL1828814 | 0.78 | NOS2 (0.52) | NOS2NOS3NOS1 | |
| SCHEMBL16346063 | 0.78 | NOS2 (0.52) | NOS2NOS3NOS1RAB9ADYRK1A | |
| SCHEMBL26537579 | 0.78 | NOS2 (0.52) | NOS2NOS3NOS1RAB9A | |
| SCHEMBL8364029 | 0.77 | NOS2 (0.50) | NOS2NOS3NOS1RAB9ADYRK1A | |
| SCHEMBL11030279 | 0.76 | CCR1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894784-B2 | Heteroarylbenzimidazole compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-01-19 | — | — | US | disclosed |
| US-20190047980-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-02-14 | — | — | US | disclosed |
| WO-2017102091-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047980-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | CCNI, CCNT2, CDK2 | NOS2 1181/4885NOS3 1635/4885NOS1 2141/4885 |
| US-10894784-B2 | Heteroarylbenzimidazole compounds | CCNI, CCNT2, CDK2 | NOS2 1181/4885NOS3 1635/4885NOS1 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.